CorMedix DefenCath Receives Vizient Recognition for Hemodialysis Infection Reduction

CorMedix Inc. announced on October 23, 2025, that Vizient recognized DefenCath, its FDA-approved antimicrobial catheter lock solution. The device targets adult patients undergoing chronic hemodialysis using a central venous catheter. Clinical trial data from the Phase 3 LOCK IT-100 study demonstrated that DefenCath reduced the risk of catheter-related bloodstream infections by 71 percent. Adverse events reported were comparable to the control group. CorMedix is currently conducting a real-world evidence study involving over 2,000 patients, with interim data expected by year-end. Vizient, a major healthcare performance improvement company, manages approximately $156 billion in annual purchasing volume. This recognition increases DefenCath's visibility and potential adoption among healthcare providers. DefenCath is the first and only antimicrobial catheter lock solution approved by the FDA in the United States. The Vizient designation may further accelerate its integration into clinical practice by increasing awareness of the product's benefits in reducing infections associated with hemodialysis catheters.